Skip to main content

Day: September 16, 2020

Vericel Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

CAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ: VCEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the recently submitted Biologics License Application (BLA) for NexoBrid® (concentrate of proteolytic enzymes enriched in bromelain) for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. The FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of June 29, 2021. In addition, the FDA communicated that it is not currently planning to hold an advisory committee meeting to discuss the application. “The FDA’s acceptance of the NexoBrid BLA for review represents another important milestone toward our goal of providing a new standard of care for eschar removal in patients with severe burns,” said Nick...

Continue reading

MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

YAVNE, Israel, Sept. 16, 2020 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (the “MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its recently submitted Biologics License Application (BLA) for NexoBrid® for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.  The FDA assigned a Prescription Drug User Fee Act (PDUFA) target date of June 29, 2021.  In addition, the FDA communicated that it is not currently planning to hold an advisory committee meeting to discuss the application.“The FDA’s acceptance of the NexoBrid BLA submission for review is a major milestone for MediWound, and it is gratifying...

Continue reading

DraftKings and New York Giants Announce Official, Exclusive Sports Betting Deal

BOSTON, Sept. 16, 2020 (GLOBE NEWSWIRE) — Today, the New York Giants and DraftKings (Nasdaq: DKNG) announced an exclusive, multi-year arrangement, making DraftKings the Official Sports Betting, iGaming and Daily Fantasy operator of the team. This multi-faceted arrangement grants DraftKings access to official Giants marks and logos, in addition to a first of its kind virtual SportsLounge open on Giants’ game days, providing attendees with unique and innovative ways to engage on all DraftKings platforms.“The New York Giants have continued to be a fantastic organization to work with over the years, and we are excited to expand our relationship as the Giants’ Official Exclusive Sports Betting, iGaming and Daily Fantasy operator,” said Ezra Kucharz, DraftKings’ Chief Business Officer. “Both organizations remain committed to customer...

Continue reading

Flyht Works to Speed Aviation Industry Recovery with New Actionable Intelligence Suite of Applications

CALGARY, Alberta, Sept. 16, 2020 (GLOBE NEWSWIRE) — FLYHT Aerospace Solutions Ltd. (TSX-V: FLY) (OTCQX: FLYLF) (the “Company” or “Flyht”) today announced that the Company has developed and is delivering phase one of the Actionable Intelligence suite of SaaS applications. These developments will enable Flyht to combine its proven history of collecting, analysing and reporting aircraft operational data with IBM Watson Knowledge Catalog and IBM Cloud Pak for Data to enhance efficiency, cost and the goal of on time operations for clients like China Express Airlines, Swoop Airlines and its other global customers.  Flyht currently has more than 2,800 aircraft equipped with the patented AFIRSTM system, and provides data analytics and reporting to more than 80 aircraft operators around the globe. The operation supports airlines 24/7 as...

Continue reading

Zai Lab Launches Hong Kong Secondary Listing

SHANGHAI and SAN FRANCISCO, Sept. 16, 2020 (GLOBE NEWSWIRE) — Zai Lab Limited (“Zai Lab” or the “Company”) (NASDAQ:ZLAB), an innovative commercial stage biopharmaceutical company, today announced the launch of its Hong Kong public offering (the “Hong Kong Public Offering”), which forms part of the global offering (the “Offering”) of 10,564,050 new ordinary shares (the “Offer Shares” or “Shares”) and listing of its ordinary shares on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) under the stock code “9688”.The Company’s American depositary shares (“ADSs”), each representing one (1) ordinary share of the Company, will continue to be listed and traded on the Nasdaq Global Market (“Nasdaq”). Investors in the Offering will only be able to purchase ordinary shares and will not be able to take...

Continue reading

ArcAroma AB: 200916 ArcAromas styrelse och personal/nyckelpersoner förvärvar teckningsoptioner

Pressmeddelande 2020-09-16ArcAromas styrelse och personal/nyckelpersoner förvärvar teckningsoptionerTeckningstiden i ArcAroma AB:s (ArcAroma) emission av teckningsoptioner inom incitamentsprogrammen ArcAroma TO 1 och ArcAroma TO 2 avslutades den 15 september 2020. Styrelse och personal tecknade totalt 701 000 optioner för priset 0,38 kr per option. Teckningen fördelades på 150 000 optioner till styrelsen och 551 000 optioner till personal och nyckelpersoner. Ytterligare 139 300 optioner har placerats i depå inför planerad rekrytering av nyckelpersoner. Vid bolagsstämman den 17 juni 2020 beslutades om ett optionsprogram riktat till styrelseledamöter, personal och externa nyckelpersoner i bolaget. Optionsvillkoren baseras på en marknadsmässig värdering enligt Black & Scholes-modellen, med utgångspunkt från den volymvägda aktiekursen...

Continue reading

Clearlake Capital-Backed Provation Acquires ePreop

Minneapolis, MN and Santa Monica, CA, Sept. 16, 2020 (GLOBE NEWSWIRE) — Provation, the premier software provider of procedure documentation and clinical decision support solutions, backed by Clearlake Capital Group, L.P. (together with its affiliates, “Clearlake”), today announced its acquisition of ePreop, a leading provider of perioperative SaaS solutions designed to simplify the entire surgical encounter.For 25 years, Provation has been a market leader in procedure documentation software for gastroenterology (“GI”), serving 43 of the top 50 GI hospitals and nearly 3,500 facilities nationwide. ePreop has been providing anesthesia quality reporting and perioperative care coordination solutions for more than 10 years and serves more than 18,000 end users and 1,500 facilities with its SurgicalValet™ and AnesthesiaValet™ platforms....

Continue reading

Change in the holding of Suominen treasury shares

Suominen Corporation’s stock exchange release on September 16, 2020 at 2:00 p.m. (EEST)The decision on the directed share issue is based on the authorisation granted to the Board of Directors by the Annual General Meeting of Shareholders held on March 19, 2020.After the share delivery on September 16, 2020, the company holds a total of 690,878 treasury shares.SUOMINEN CORPORATIONFurther information:Klaus Korhonen, SVP, HR and Legal Affairs tel. +358 10 214 30 70Suominen manufactures nonwovens as roll goods for wipes and other applications. Our vision is to be the frontrunner for nonwovens innovation and sustainability. The end products made of Suominen’s nonwovens, such as wet wipes, feminine care products and swabs, are present in people’s daily life worldwide. Suominen’s net sales in 2019 were EUR 411.4 million and we have nearly...

Continue reading

Muutos Suomisen omien osakkeiden määrässä

Suominen Oyj:n pörssitiedote 16.9.2020 klo 14.00Suominen Oyj on luovuttanut vastikkeetta yhteensä 9 352 yhtiön hallussa olevaa omaa osaketta sitouttavan lisäosakejärjestelmän 2019 osallistujille sitouttamisjakson 2019-2020 perusteella järjestelmän ehtojen mukaisesti. Kannustinjärjestelmän keskeisistä ehdoista on kerrottu tarkemmin 4.6.2019 julkaistussa pörssitiedotteessa.Osakkeiden luovuttaminen suunnatulla maksuttomalla osakeannilla perustuu varsinaisen yhtiökokouksen 19.3.2020 hallitukselle antamaan valtuutukseen.16.9.2020 tapahtuneen luovutuksen jälkeen yhtiön hallussa on 690 878 omaa osaketta.SUOMINEN OYJLisätietoja:Klaus Korhonen, henkilöstö- ja lakiasiainjohtaja, puh. 010 214 3070Suominen valmistaa kuitukankaita rullatavarana pyyhintätuotteisiin sekä muihin sovelluksiin. Visiomme on olla edelläkävijä innovatiivisissa ja vastuullisissa...

Continue reading

XPO Logistics Expands Education Benefits for US Employees

GREENWICH, Conn., Sept. 16, 2020 (GLOBE NEWSWIRE) —  XPO Logistics, Inc. (NYSE: XPO), a leading global provider of transportation and logistics solutions, today announced the expansion of its Academic Partners Program benefitting hourly workers in the United States. The company’s academic partnerships make thousands of accredited courses, degrees and certifications available to US employees at large discounts.Qualifying hourly employees can couple XPO’s $5,250 annual tuition reimbursement with an Academic Partners discount to earn tuition-free college degrees in over 80 separate fields of online study. Additionally, the company’s partnership with the Massachusetts Institute of Technology Industrial Liaison Program gives employees access to MIT Sloan Executive Education and MIT Professional Education short courses at a reduced cost.Troy...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.